Agoracom Blog Home

Posts Tagged ‘Cannabis’

Empower Clinics $CBDT.ca Reports 2Q 2019 Results Highlighted by an 89% increase in clinic revenues and a 37% decrease in operating expenses compared to 2Q 2018 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 7:30 AM on Wednesday, August 14th, 2019

Highlights:

  • 4,299 patient visits generated revenue of $591,024, compared to 2,187 patient visits that generated $312,485 for Q2 2018.
  • Strategic redirection: The Company has been re-positioning its overall strategy to become a vertically integrated health and wellness brand that connects to its 165,000 patients using a data driven focus to improve patients’ lives with products, technology and health systems.

VANCOUVER, Aug. 14, 2019 – EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (OTC: EPWCF) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics in the U.S., has filed today its unaudited interim condensed consolidated financial statements for the three and six months ended June 30th, 2019 and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

“The impact of cost cutting measures and the benefit of the Sun Valley acquisition are now showing up in the financial statements of the Company” said Steven McAuley, Empower’s Chairman & CEO. “Even though we can only book two months of Sun Valley’s performance in 2Q, the significance is notable, and we expect continued benefits going forward, especially with the new retail product strategy in-clinics and with the franchise program.”

Q2 2019 Highlights

  • 4,299 patient visits generated revenue of $591,024, compared to 2,187 patient visits that generated $312,485 for Q2 2018.

  • Net loss of $1,456,505, compared to $3,915,443 for Q2 2018, which was primarily driven by significantly reducing operating costs through aggressive headcount cuts, facility changes and lower stock-based compensation expense.

  • Cash used in operating activities was $1,331,950 for YTD 2019, compared to $2,358,949 for YTD 2018.

  • Cash at June 30, 2019 of $817,168, compared to $157,668 at December 31, 2018, which was primarily driven by equity financings during the six months ended June 30, 2019.

Recent Highlights

  • Strategic redirection: The Company has been re-positioning its overall strategy to become a vertically integrated health and wellness brand that connects to its 165,000 patients using a data driven focus to improve patients’ lives with products, technology and health systems.

  • Strengthened Management Team: In January 2019, seasoned entrepreneur and executive officer and former GE Capital Managing Director Steven McAuley was appointed as Empower’s Chairman & CEO. The Empower management team has since been augmented with critical hires made from the ranks of investment banking, accounting, marketing and clinic operations among other disciplines. CFO Mat Lee, appointed on March 19, 2019, is an experienced accounting and finance executive. To further support financial and accounting restructuring, the Company engaged the services of Invictus Accounting Group, a top-tier boutique advisory firm based in Vancouver, BC.

  • Experienced and Seasoned Board of Directors: The Company Board of Directors includes its CEO Steven McAuley, Dustin Klein, the Co-Founder of Sun Valley Clinics and the SVP, Business Development and Andrejs Bunkse, owner and practicing attorney of Rain Legal and Counsel to numerous cannabis enterprises in the U.S. and Canada.

  • Strategic Acquisition: On May 1, 2019, the Company completed the acquisition of Sun Valley Certification Clinics Holdings LLC (“Sun Valley”) from Andrea Klein and Dustin Klein and two minority shareholders, through its wholly-owned subsidiary Empower Healthcare Assets Inc., for consideration having an aggregate value of $3,960,000. Sun Valley operates a network of professional medical cannabis and pain management practices, with five clinics in Arizona, one clinic in Las Vegas, a tele-medicine platform serving California, and a fully developed franchise business model for domestic and international markets.

  • Strategic Development: The Company has opened its first hemp-derived CBD extraction facility in greater Portland, Oregon with the first extraction system expected to have the capacity to produce 6,000 kg of extracted product per year. The Company took possession of the new extraction facility June 1st, 2019 and has recently been awarded it’s hemp-handlers licence from the Oregon Department of Agriculture, allowing the Company to enter the next phase of build-out and full operations in 2019.

2019 Outlook and Catalysts

  • Enhanced Corporate Governance: The Company has prioritized corporate governance practices under the leadership of its Board of Directors and Chairman Steven McAuley, to ensure financial and accounting controls operate at the highest of standards.

  • Improved Capital Markets Profile: Empower is diversifying its business model to become a vertically integrated operator in the global cannabis sector with a focus on patient care, CBD product distribution, research & development and CBD product extraction. The Company believes this will appeal to a broader base of shareholders and investors and provide greater access to capital and improved trading liquidity.

  • Increased Patient Access: With a rapidly expanding company-owned clinic network and significant expansion opportunity through the Sun Valley Health franchise model, Empower anticipates it will grow its total patient list substantially in the years ahead. This is expected to provide greater opportunity for treatment analysis using artificial intelligence (AI), through progressive initiatives that include adding the Endocanna DNA test kit to the Company product & service offering in clinics and online. Ensuring the Company is a leader in understanding the efficacy of cannabis-related treatment options is an imperative.

  • Focus on CBD Product Sales: The Company has launched its online store to sell its lines of hemp-derived CBD based products and premium health & wellness supplements. Customers can purchase products, including CBD lotions, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet-elixir hemp extract drops. Patients and customers will be able to access Sun Valley Health customer service, home delivery and e-commerce platforms.

  • Market Leading Technology: Empower utilizes market-leading patient electronic management and POS system that is HIPAA compliant and provides deep insight to patient care. The Company supports remote patients using its tele-medicine portal, enabling patients who do not live near one of its clinic locations, or are disabled or unable to come to a location, to still benefit from a doctor consultation.

  • Launches Nationwide Franchise: The Company has launched its nationwide franchise program under the Sun Valley Health brand to dramatically grow our clinic & store footprint increasing direct access to patients and to sell hemp-derived CBD products and premium wellness products directly to our customers and online at our new e-commerce store at www.sunvalleyhealth.com

  • Opens CBD Extraction Facility: The Company has opened its first hemp-derived CBD extraction facility near Portland, OR in a region that is surrounded by numerous licensed hemp farms, that has the potential to produce 6,000kg of extraction distillate or isolate to serve the Company’s own CBD product lines and other third party processing contracts.

Financial Summary

$, except where noted Three months ended June 30, Six months ended June 30,
  2019 2018 2019 2018
Patient visits 4,299 2,187 5,497 4,429
Clinic Revenues 591,024 312,485 743,869 614,627
Direct Clinic Expenses (82,750) (107,271) (122,163) (212,436)
Loss from operations (1,424,070) (2,703,891) (1,703,379) (3,311,426)
Net loss (1,456,505) (3,915,443) (1,855,047) (3,754,191)
Net loss per share (0.01) (0.06) (0.02) (0.08)

Financial Performance

Clinic revenues for Q2 2019 were $591,024, compared to Q2 2018 revenues of $312,485. This increase over the prior year is attributable to the acquisition of Sun Valley Clinics effective May 1, 2019, and includes two months of accretive revenue. Future results will include a full three months of results of Sun Valley in quarters going forward.

Direct clinic expenses for Q2 2019 were $82,750, compared to Q2 2018 direct clinic expenses of $107,271. These expenses declined despite the increase in revenues due to improved operational controls to align labor cost with direct patient consultations. The Company employs a diverse mix of physicians and practitioners.

Net loss from operations for Q2 2019 was $1,424,070, compared to Q2 2018 net loss of $2,703,891. This decrease in loss below prior year is primarily attributable to two factors. Operating expense decreased due to a decrease in salaries and benefits as a result of aggressive headcount cuts and facility changes. Additionally, share-based payments decreased due to timing of share-based awards to management.

Net loss for Q2 2019 was $1,456,505, respectively, compared to Q2 2018 net loss of $3,915,443. This decrease over prior year is primarily attributable to the decrease in operating expenses and share-based compensation expense. In addition, Q2 2018 included listing fees associated with the RTO.

During Q2 2019, the Company used $1,331,950 in cash from operations after changes in non-cash working capital. The Company invested $543,573 for the acquisition of Sun Valley Clinics and raised $2,576,907 via proceeds from various issuances of shares, convertible debentures and notes.

Please refer to the Company’s unaudited condensed interim consolidated financial statements, related notes and accompanying management discussion and analysis for a full review of the operations.

ABOUT EMPOWER

Empower is a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics, operating the Sun Valley Health clinic brand www.sunvalleyhealth.com, for its nine corporate locations and for franchises in the United States. As a CBD product manufacturer under the Sollievo brand, the Company distributes its lines through clinics, online and through retail partners. Extraction operations are currently being developed in the Company’s new extraction facility in Oregon.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operational in 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2019/14/c3330.html

CONTACTS: Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARICopyright CNW Group 2019

INTERVIEW: Newly Listed Spyder #Cannabis $SPDR.ca Scores 5 US Retail Locations, With Possibility To Expand To 39, With US Outlet Partner $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 10:45 AM on Tuesday, August 13th, 2019

Spyder Cannabis (SPDR:TSXV) went public just a couple of months ago and hit the ground running with 5 operating Canadian retail locations – and a 6th one on the way via an 8,000 sq ft super store in Alberta.  
Most companies would be ecstatic to have this number of locations – but Spyder just announced a major move into the United States, with a 5 location deal for boutique stores up and down the US Eastern seaboard.  The news gets better.  If all goes well with these 5 locations, the US outlet partner has a total of 39 locations across 20 states for Spyder to grow into to.

Spyder Cannabis may have just gone public but they are making big moves into the highly coveted retail space for marijuana, CBD and Hemp products, including carrying their own brands within their stores.

Grab your favourite cold summer beverage and watch this interview with CEO, Dan Pelchovitz.

BREAKING: Spyder Cannabis $SPDR.ca Signs Retail Agreement with Tanger Outlet $SKT Gaining Access to Millions of Consumers Coast-to-Coast in the U.S. $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 7:35 AM on Tuesday, August 13th, 2019
  • Spyder to open 5 hemp boutique locations at Tanger Outlet centers throughout the United States
  • Agreement will expand Spyder’s physical footprint to a projected 11 total locations by the end of this year
  • Potential for additional locations in the future

Vaughan, ON, August 13, 2019, Spyder Cannabis Inc. (“Spyder“), an established Canadian cannabis and vape retail operator, announced today an arrangement through which Spyder will open 5 hemp boutique locations with potential for more at Tanger Outlet centers throughout the United States.

This agreement will expand Spyder’s physical footprint to a projected 11 total locations by the end of this year, with the potential for additional locations in the future.  â€œTanger Outlet operates 39 upscale outlet shopping centers located in 20 states coast to coast and will allow us access to millions of consumers,” stated Daniel Pelchovitz, CEO and President of Spyder. “They offer a superior outlet experience and deep tenant relationships, and we are excited to introduce our hemp retail to their centers.”

These boutiques will stock Spyder’s SPDR (R) branded hemp derived, and infused products developed for an aging, health and wellness demographic.  Spyder will offer a wide array of hemp product offerings including; hemp -infused muscle balm, face oil, body lotion and bath salts, as well as hemp tinctures, capsules and sprays.

The hemp industry is booming and has the potential to become a $22 billion business by 2022, according to cannabis-focused research firm Brightfield Group. Spyder plans on executing an aggressive expansion plan to create a significant retail brand in the U.S. hemp market and is committed to developing and acquiring prime North American retail locations and continuing to build its fast growing brand.

About Spyder Cannabis

Founded in 2014 Spyder is an established chain of three high-end vape stores, and two cannabis accessory stores, in Ontario, with locations in Woodbridge, Scarborough, Burlington, Pickering and Niagara Falls. The Spyder brand is defined by its high-quality proprietary line of e-juice, liquids and exclusive retail deals, dispensed in uniquely designed stores creating the optimal customer experience.  Spyder is building off this leading retail, distribution and branding eCig and vapes company and is pursuing expansion into the legal cannabis and hemp derived market.  Spyder has developed a scalable retail model with plans to create a significant footprint with targeted and disciplined retail distribution strategy focusing on Canadian retail and U.S. boutique retail and kiosks in high traffic peripheral areas

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.

Dan Pelchovitz

President & Chief Executive Officer
Contact: Investor Relations
Phone: 1-888-504-SPDR (1-888-504-7737)

Email: [email protected]

Empower Clinics $CBDT.ca Receives Approval from #SQUARE to Process #CBD Product Sales in Clinics, Stores, Online, and throughout the Company Network Nationwide in the U.S. $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 8:18 AM on Monday, August 12th, 2019
  • Announced it has received approval from SQUARE, Inc. to accept card payments
  • Patients and customers can now purchase hemp-derived CBD products and diverse wellness products from Empower Clinics & Sun Valley Health online and in-store using the SQUARE payment processing system

VANCOUVER, Aug. 12, 2019 – EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (OTC: EPWCF) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics in the U.S., is pleased to announce it has received approval from SQUARE, Inc. to accept card payments from customers that want to purchase CBD products and other wellness products from the Company in clinics, stores and online.

Patients and customers can now purchase hemp-derived CBD products and diverse wellness products from Empower Clinics & Sun Valley Health online and in-store using the SQUARE payment processing system, ensuring ease-of-use and a positive checkout experience.

“Providing our patients and customers with card payment options for CBD product purchases is imperative and the fact that SQUARE has approved us, affirms our professionalism and operating standards.” said Steven McAuley, Empowers Chairman & CEO. “The addition of SQUARE merchant services provides our customers the ability to purchase products in a simple and user-friendly manner, something that we all take for granted each day.”

Square tells its users online that, “We believe everyone should be able to participate and thrive in the economy.” They also say “That no one should be left out of the economy because the cost is too great, or the technology too complex.”

Merchant services enable businesses to accept credit and debit card payments from customers. Empower Clinics and its subsidiaries, have stable and strong partnerships with commercial banking providers in the Pacific Northwest and in Arizona.

About SQUARE

Square, Inc. is a financial services and merchant services aggregator, and mobile payment company based in San Francisco, California. The company markets several software and hardware payments products and has expanded into small business services.

ABOUT EMPOWER

Empower is a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics, operating the Sun Valley Health clinic brand www.sunvalleyhealth.com, for its nine corporate locations and for franchises in the United States. As a CBD product manufacturer under the Sollievo brand, the company distributes its lines through clinics, online and through retail partners. Extraction operations are currently being developed in the Company’s new extraction facility in Oregon.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operation by Q2 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2019/12/c2706.html

AGORACOM Welcomes EMPOWER CLINICS $CBDT.ca with a patient count of 165,000 and a platform generating $5MM USD in revenue annually (2020) $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 2:30 PM on Friday, August 9th, 2019
(CSE: CBDT) (Frankfurt 8EC) (OTC: EPWCF)

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Launching CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

Recent Acquisition of Sun Valley Certification Clinics Holdings LLC

  • Created one of the largest clinic groups in the medical cannabis sector in the United States
  • Twelve (combined) clinic locations
  • Combined patient count of 165,000 patients
  • Platform generating $5MM USD in revenue annually (2020)
  • Operating in Washington, Oregon, Arizona, Nevada and California

According to the Brightfield Group report the CBD market in the U.S. has grown over 700% in 2019

  • The CBD industry is becoming much more saturated than it was before the passing of the U.S. Farm Bill late last year, with new products entering the market, threatening to take a slice of the CBD pie that the early producers of CBD have enjoyed until this time.
  • Nevertheless, the top 20 CBD companies still hold a majority of the even bigger pie that is CBD in the cannabis industry.

Technology

Developed proprietary software to manage patients through the medical cannabis process

  • A HIPAA compliant Electronic Health Record (EHR) system and patient management portal.
  • Tele-medicine platform to serve and treat patients remotely.
  • Launching an e-Commerce platform for it’s Sollievo and Sun Valley CBD product lines.


 Products

  • Commenced selling its proprietary line of CBD-based products called SOLLIEVO
  • Empower’s patient base and customers are expected to benefit from access to high margin derivative products, including CBD lotion, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet elixir hemp extract drops.
  • Patients and customers will be able to access Empower’s home delivery and e-commerce platform.

CBD Extraction

  • Opening first CBD Extraction facility in Portland, OR.
  • 5,000 sq. ft. leased building with first extraction system capable of producing 20kg per day of 99% spectrum oil, isolate or distillate
  • Current wholesale pricing is $6,500 USD per kg with annual capacity of 6,000kg an estimated $39MM USD revenue.
  • Facility can scale to four extraction systems for up to 24,000kg of product and over $150MM USD revenue

Franchising

  • Completed it’s 2019 Franchise Disclosure Document (FDD) and has commenced selling Sun Valley Health franchises in the United States.
  • Company is now selling Sun Valley Health franchises and is accepting franchise applications effectively immediately.
  • Invested in the development of a new franchise trade show booth that showcases the Sun Valley Health opportunity to perspective franchisees using dynamic, content rich displays and four large format television monitors to present features and benefits.

 Summary

CLIENT FEATURE: Vertical Exploration $VERT.ca – Pairing Wollastonite and Kootenay Cup to Win Best Marijuana Flower $TORR.ca $FA.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM at 10:20 AM on Friday, August 9th, 2019

Kootenay Cup – B.C. Buds Testing Confirms Wollastonite is Critical to Marijuana Growers

  • Vertical is researching the use of Wollastonite as a soil additive for optimizing marijuana growth
  • Phase Three trials involving cannabis grown with Wollastonite (CaSiO3) as a soil additive at BC Bud Depot’s (BCBD) ACMPR-licenced Research and Development facilities in Vancouver, BC
  • Phase Three trials measured and recorded significant improvements in root mass, powdery mildew control and pest elimination.
  • In every case the most optimal results occurred with an admixture rate of 10% to 15% Wollastonite to the growth medium

WOLLASTONITE

  • St-Onge-Wollastonite Deposit located approximately 90 kilometres Northwest of the city of Saguenay, in St-Onge township, in the Saguenay-Lac-St-Jean region of Quebec, Canada.
  • Wollastonite is a calcium inosilicate mineral that may contain small amounts of iron, magnesium, and manganese substituting for calcium
  • Research and testing in the Phase 1 program for use in cannabis growth was managed and monitored by AGRINOVA, a highly-regarded Center for Research and Innovation in Agriculture in Quebec

St-Onge-Wollastonite Deposit:

Vertical Exploration Hub on Agoracom

FULL DISCLOSURE: Vertical Exploration is an advertising client of AGORA Internet Relations Corp.

Spyder Cannabis $SPDR.ca – U.S. #CBD Sales to Grow an Average of 107% Annually Through 2023 $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 2:56 PM on Thursday, August 8th, 2019

SPONSOR: Spyder Cannabis Inc. (TSX-V: SPDR) An established chain of high-end vape stores in Ontario, Canada. The company has an aggressive expansion plan already in place that will focus on Canadian retail and US Hemp-Derived kiosks in high traffic areas. Click here for more info.

(TSX-V: SPDR)

A new report projects nearly $24 billion in U.S. cannabidiol sales by 2023.

By: Sean Williams

  • It’s no secret by now that the marijuana industry is a big-money business.
  • Having grown from $3.4 billion in legal global sales in 2014 to hit nearly $11 billion worldwide in 2018, it demonstrates just how quickly “going green” is catching on with consumers and investors.

However, there’s a potentially larger growth trend contained within the cannabis movement that investors simply have to know about: Cannabidiol (CBD).

Image source: Getty Images.

CBD growth could be off the charts

Cannabidiol is the nonpsychoactive cannabinoid that’s best known for its perceived medical benefits. Since products infused with CBD don’t get the user high, it has substantially broader appeal than products containing tetrahydrocannabinol (THC), the cannabinoid that gives consumers a buzz.

Further, CBD can be extracted from both the cannabis and hemp plant, whereas THC derives almost entirely from the cannabis plant, since hemp often contains very low levels of THC. Hemp plants are considerably cheaper to grow than cannabis, making hemp the preferred crop choice for CBD extraction.

The big question is: Just how big could the CBD market be?

Predictive analysis and market research company Brightfield Group believes it has the answer.

In a newly released report from Brightfield, the company is calling for year-over-year CBD product sales growth in the United States of 706% in 2019 to around $5 billion — not a typo – and sales of $23.7 billion by 2023. Comparatively, about $620 million worth of CBD products were sold last year in the United States (based on 706% growth to $5 billion). Growing CBD revenue from about $620 million in 2018 to $23.7 billion by 2023 works out to (drum roll) a compound annual growth rate (CAGR) of a whopping 107%! Compare that to some of the most robust broad-based growth estimates for cannabis, which call for a CAGR of around 25%, and you can see why CBD is all the buzz (without creating an actual buzz) on Wall Street.

Probably the next question on your mind is: How is such phenomenal growth possible?

According to the Brightfield Group, there are a number of catalysts fueling CBD’s rise.

Image source: Getty Images.

General retailers are stepping up

First, it sees significant sales growth from the entrance of major pharmacy chains into the CBD space. As you may be aware, CVS Health (NYSE:CVS) kicked things off in March by announcing plans to carry CBD topicals in approximately 800 stores across eight states. Walgreens Boots Alliance (NASDAQ:WBA) followed suit just days later by announcing its intention to carry CBD topicals in 1,500 stores in a handful of states. Rite Aid (NYSE:RAD) was last to join the party, with the company carrying CBD topicals in Washington and Oregon.

Traditionally, pharmacy chains are a low-margin business. Though the bulk of profits are derived from the pharmacy side of the equation, front-end store products are what can drive consumer loyalty and foot traffic. By adding CBD products to their stores, CVS Health, Walgreens Boots Alliance, and Rite Aid, are likely hoping that it brings in repeat business and new consumers.

Don’t overlook the role CVS Health, Walgreens, and Rite Aid have played in paving the way for other general retailers to carry CBD products. National grocery chain Kroger (NYSE:KR) recently announced plans to carry CBD items in 17 states, with Harvest Health & Recreation landing a game-changing partnership to supply CBD products to at least 10,000 gas-station convenience stores.

Image source: Getty Images.

Canadian licensed producers will soon make their mark

Secondly, Brightfield Group notes that Canadian marijuana producers entering the U.S. hemp market are bound to make a splash.

To date, nearly half of Canada’s major growers (i.e., those capable of at least 100,000 kilos of cannabis output per year) have announced their intention to enter the U.S. hemp market. This has been made possible as a result of President Trump signing the farm bill into law in December. This law legalizes the industrial production of hemp and hemp-derived CBD.

Read More: https://www.fool.com/investing/2019/07/14/us-cbd-sales-to-grow-an-average-of-107-annually-th.aspx

North Bud Farms Inc. $NBUD.ca – Drink Makers Seek to Include #CBD and #Cannabis Beverage Alternatives $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 11:09 AM on Wednesday, August 7th, 2019

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

Drink Makers Seek to Include CBD and Cannabis Beverage Alternatives

  • According to data compiled by Fior Markets, the global cannabis beverages market is expected to reach USD 4.56 Billion by 2025 while exhibiting a CAGR of 16.8% during the forecast period from 2018 to 2025.
  • In particular, edibles are more abundant in regions where recreational cannabis is legal. On the other hand, the cannabis-infused beverage industry is experiencing significant strength because of large beverage corporations entering into the marketspace.

NEW YORK, Aug. 7, 2019 — As the cannabis industry continues to develop, savvy consumers and businesses are creating innovative new ways to ingest cannabis. Due to widespread stereotypes, many imagine cannabis users relying on hastily rolled joints. However, as the legal industry continues to accelerate, new products are constantly emerging. For instance, in legal markets such as Colorado or California, extracts and concentrates have become increasingly popular because of their potency and immediate effects. Specifically, Colorado has witnessed its extract and concentrate sales eclipse its flower sales in recent years. And while extracts and concentrates are widely popular, other vendors have incorporated cannabis into edibles and beverages.

In particular, edibles are more abundant in regions where recreational cannabis is legal. On the other hand, the cannabis-infused beverage industry is experiencing significant strength because of large beverage corporations entering into the marketspace. Notably, big alcohol has set its sights on the cannabis market because of its declining primary revenue drivers. As a result, many companies are adding cannabis-infused beverages to their product lines in order to combat lower sales numbers that are a result of the declining alcohol consumption levels. However, to note, most companies are predominantly only adding CBD, or cannabidiol, to their beverages because of regulatory restrictions on THC.

Moreover, companies are marketing CBD-infused beverages as health and wellness products rather than recreational or relaxation products. And while the infused beverage market is already experiencing a surge in momentum in legal regions, it’s expansion into new territories is expected to spur its growth. According to data compiled by Fior Markets, the global cannabis beverages market is expected to reach USD 4.56 Billion by 2025 while exhibiting a CAGR of 16.8% during the forecast period from 2018 to 2025.

Source: https://www.prnewswire.com/news-releases/drink-makers-seek-to-include-cbd-and-cannabis-beverage-alternatives-300897989.html

Empower Clinics $CBDT.ca Enters Into Strategic Partnership With Heritage #Cannabis Subsidiary Endocanna Health to Create and Sell #Endocannabinoid DNA Test Products $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $CANN.ca

Posted by AGORACOM-JC at 8:35 AM on Wednesday, August 7th, 2019
  • Entered into a strategic partnership with Endocanna Health Inc. a research and development biotechnology company specializing in endocannabinioid DNA testing, and a partly owned subsidiary of Heritage Cannabis (CSE: CANN)
  • Endocanna will manufacture its patent-pending Endocannabinoid DNA Test Kits for and license its proprietary DNA technology to Empower.

VANCOUVER, Aug. 7, 2019  – EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (OTC: EPWCF) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics in the U.S., is pleased to announce it has entered into a strategic partnership with Endocanna Health Inc.(“Endocanna“), a research and development biotechnology company specializing in endocannabinioid DNA testing, and a partly owned subsidiary of Heritage Cannabis (CSE: CANN)

Endocanna will manufacture its patent-pending Endocannabinoid DNA Test Kits for and license its proprietary DNA technology to Empower. Empower will immediately make the Endocanna kits available to its corporate owned medical clinics that include 165,000 patients in Oregon, Arizona, Washington State and Nevada. The Company plans to include the DNA Test Kits as a standard offering in the Sun Valley Health franchise program, and has commenced it’s roll-out in the United States.

“We continue to focus our initiatives on patient care and wellbeing, ensuring we have the ability to provide best-in-class care and advice using the most advanced technology available.” said Steven McAuley, Empowers Chairman & CEO. “The Endocanna DNA Test Kit can give our physicians the potential to have even greater insight into each individual patient’s propensity for success, on how CBD based therapies may interact with their individual regulatory system.”

The Kits are designed to provide consumers with personalized data about how cannabidiol (CBD) and other cannabinoids may interact with their body, plus the technology may allow the company to provide patients with science-backed cannabis product suggestions based on their specific DNA.

“Using Endocanna Health’s proprietary DNA report, we can personalize and provide a cannabinoid wellness protocol tailored to an individual’s needs.” said Len May, CEO & Co-Founder of Endocanna Health. “Empower and their Sun Valley Health clinic network, provides an immediate opportunity for us to work with physicians and patients to develop advanced science surrounding the endocannabinioid system and CBD based therapies.”

About Endocanna Health Inc.

Endocanna is a company based in Los Angeles, CA that has developed Endocannabinoid DNA testing to assist individuals in taking control of their own health, by utilizing cannabis products specifically suited for themselves. The recently expanded database of genetic markers now allows for a thorough review of potential products, which are helpful to address the needs of patients. EndoDNA testing packages are currently available in the United States, and will shortly be introduced to Canada and other select cannabis-forward countries. For more information visit www.endocannahealth.com 

About Heritage Cannabis Holdings Corp.

The Company is focused on becoming a vertically integrated cannabis provider that currently has two Health Canada approved licenced producers, through its subsidiaries Voyage Cannabis Corp. and CannaCure Corp. both regulated under the Cannabis Act Regulations. Working under these two licences, Heritage has two additional subsidiaries, Purefarma Solutions, which provides extraction services, and BriteLife Sciences that is focused on cannabis based medical solutions. Heritage as the parent Company, is focused on providing resources for its subsidiaries to advance their products or services to compete both domestically and internationally.

ABOUT EMPOWER

Empower is a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics, operating the Sun Valley Health clinic brand www.sunvalleyhealth.com, for its nine corporate locations and for franchises in the United States. As a CBD product manufacturer under the Solievo brand, the company distributes its lines through clinics, online and through retail partners. Extraction operations are currently being developed in the Company’s new extraction facility in Oregon.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operation by Q2 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2019/07/c1240.html

Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARICopyright CNW Group 2019

Spyder Cannabis $SPDR.ca – Retailers See Promise in #CBD and #Hemp Products $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 9:15 PM on Tuesday, August 6th, 2019

SPONSOR: Spyder Cannabis Inc. (TSX-V: SPDR) An established chain of high-end vape stores in Ontario, Canada. The company has an aggressive expansion plan already in place that will focus on Canadian retail and US Hemp-Derived kiosks in high traffic areas. Click here for more info.

(TSX-V: SPDR)

Retailers See Promise in CBD and Hemp Products

CBD Hemp oil, Doctor holding a bottle of hemp oil, Medical marijuana products including cannabis leaf, cbd and hash oil, alternative medicine

Dennis Mitzner Contributor

Thanks to the passing of the Farm Bill in late 2018 – containing a provision legalizing hemp, a species of non-psychoactive cannabis that CBD can be extracted from – Hemp and CBD are on major retailers’ radar. 

The CBD market is moving towards mainstream retailers and is projected to be over $20 Billion in sales by 2024. Walgreens, Sprout, CVS, Ulta Beauty, GNC Holdings, Urban Outfitters are just a handful of retailers offering or looking to offer, CBD products to consumers.

According to Christina Hartwell from Little Mary and Jane â€the industry is on the verge of moving beyond merely CBD and exploring the full spectrum of Hemp (Cannabis Sativa L).”

The potential of CBD and Hemp products appears to be endless due to newly emerging scientific data.

“The industry is on the verge of moving beyond merely CBD and exploring the full spectrum of Hemp (Cannabis Sativa L). Scientific studies thus far have been somewhat limited due to the stumbling block of THC due to potential adverse side effects and regulations. However, the studies being done on full-spectrum Hemp and the multitude of Cannabinoids in the plant are promising, CBN is beginning to come to the forefront and is potentially more beneficial for treating Insomnia and Anxiety than Isolated CBD,” Hartwell added.

Retailers jumping in

Several retailers for natural supplements are expected to have CBD on their shelves. Dillards Department Store, a chain with a total of approximately 292 stores in 29 states, is beginning to roll out several Hemp Depot while labeled CBD products. Kroger announced in July another 1,000 locations in 22 states where their grocery stores will begin to carry CBD products. 

“Because of the tremendous range of products in which CBD is a fit, we expect to see it on shelves, literally, everywhere. Wholesale order numbers are climbing dramatically, which is one of the first signs of significant market expansion. When we started, we were taking orders for small companies ordering 500 units at a time. Large company orders are projected to reach 100,000+ units in the next 18 months which is going allow wholesalers like Hemp Depot to manufacture products on a larger scale, thereby reducing CBD product prices by the end of 2020 to a forecasted $20 – $30 as with standard vitamin supplements,” said Andy Rodosevich, CEO and Co-Founder of Hemp Depot.

In July, adding to the momentum, Toronto-headquartered Abacus Health Products announced new retail purchase orders from CVS for its line of CBDMEDIC pain relief and skincare products, sold to consumers via retail chains and the company’s e-commerce platform. 

“We are encouraged to see the continued interest and growth in CBDMEDIC among leading retailers throughout the United States. In particular, the fact that CBDMEDIC products are now being positioned in-line demonstrates the acceptance of our over-the-counter products within the traditional pain relief and skincare categories and we look forward to seeing the continued growth in the number of retail locations in which CBDMEDIC is available,” said Perry Antelman, the CEO of Abacus Health Products, maker of CBD CLINIC and CBDMEDIC.

Also in July, Green Growth Brands announced a deal with American Eagle to begin selling its CBD-infused body-care products — including muscle balms and lotions — in nearly 500 of American Eagle’s stores and online, with sales expected to begin in October. This follows apparel retailer Abercrombie, which just last month announcing its plans to sell GGB’s products in more than 160 stores across the U.S.

“The cultural conversation around CBD is growing and I think we are beyond CBD being only for early adopters. The push to major retail outlets like Kroger, Walgreens, and CVS seem to support that, said Paul Miller from Lokus Nutrition.

Risks remain

The FDA is in the midst of creating guidelines for CBD manufacturers and will likely eliminate some manufacturers currently participating in the CBD boom and open the door to some large scale, mainstream manufacturers. The details of the FDA regulations will inform the specifics of how large the OTC piece of the CBD pie becomes. 

“We’ve seen major chain retailers like CVS, Walgreens, and Whole Foods start to include CBD in their product mixes. The larger the entity, the more likely they are to stick with topical products until the FDA provides clarity,” said Kate Heckman from Stratos CBD.

When it comes to CBD oils, presently only 10% of demand is being filled by present growers, the industry has increased by 200% from 2017 to 2018, about 618 million in sales last year with projected 22 Billion by 2022.

“A lot of people want to get into this arena. Some of the problems we are working on are Standardization of the industry, Genetic variations, for patents and Lab Certification. It is the wild west, with little or no standard dosages or diagnosis for the public to rely on,” said John Sation, Clinic Director, and research Coordinator from Hair & Scalp Clinics.

The recent FDA warning letter to Curaleaf on July 26 serves as a wake-up call to the industry about statements in marketing or social media that imply that these products can be used to treat medical conditions. 

“It’s in the best interest of the industry to be careful and conservative with any label claims being made. With the passing of the 2018 Farm Bill, each state department of agriculture must submit a state management plan to the USDA outlining how various aspects of hemp cultivation and processing will be managed within their jurisdiction,” said Dr. Sean Callan, CEO of Precision Botanical.

While the opportunity is real, risks remain. According to David Gross from Strategic Value Partners, players in the space should tread carefully as the regulatory framework is currently only taking shape. 

“Don’t be first here. By all indications, the FDA appears poised to take aggressive and decisive action, as evidenced by the Curaleaf warning letter, against companies who manufacture, distribute, and retail CBD products. Moreover, the Drug Enforcement Agency (DEA), Department of Agriculture, and financial regulators (i.e., FDIC, OOC, and Federal Reserve) remain unknowns. In the near-term, any benefit you might receive from being first is far outweighed by the business and reputational risk of a potential FDA action or a multi-state federal raid at your warehouses.”

Source: https://www.forbes.com/sites/dennismitzner/2019/08/06/retailers-see-promise-in-cbd-and-hemp-products/#3e264909411f